So we now have news reports and abstracts telling us what the top-line results of the SPARTAN trial and the PROSPER trial are in the treatment of men with non-metastatic, castration-resistant prostate cancer (nmCRPC). … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: apalutamide, castration-resistant, enzalutamide, nmCRPC, non-metastatic, PROSPER, SPARTAN | 17 Comments »
The Phase III PROSPER trial of enzalutamide + androgen deprivation therapy (ADT) versus a placebo + ADT in men with non-metastatic castration-resistant prostate cancer (nmCRPC) has apparently met its primary endpoint of improved metastasis-free survival. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: castration-resistant, enzalutamide, nmCRPC, non-metastatic, outcome, PROSPER, trial | 7 Comments »
According to a media release issued by Astellas Pharma and Medivation earlier today, the companies have initiated a new Phase III clinical trial to investigate the efficacy and safety of enzalutamide in the management of non-metastatic (TxNxM0), castration-resistant prostate cancer (nmCRPC). … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: castration-resistant, enzalutamide, nmCRPC, non-metastatic, PROSPER | 2 Comments »
News and information provided on this site should not be used for diagnosing or treating any health problem or disease.
The “New” Prostate Cancer InfoLink is intended for informational purposes only. It is not engaged in rendering medical advice or professional services and is not a substitute for professional care. If you have or suspect you may have a health problem, please consult your healthcare provider.
Blog at WordPress.com. WP Designer.
THE "NEW" PROSTATE CANCER INFOLINK